I

    India Globalization Capital Inc (IGC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.30
    -0.01 (-3.87%)

    Market Cap: $32.05M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(9/12)
    Avg Surprise
    -67.31%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.03-25.0%
    60d ago$-0.03-25.0%
    30d ago$-0.03-25.0%
    7d ago$-0.03-25.0%
    Current$-0.02
    Revenue Consensus
    $96000
    Range$96000 - $96000
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.03-25.0%
    60d ago$-0.03-25.0%
    30d ago$-0.03-25.0%
    7d ago$-0.03-25.0%
    Current$-0.02
    Revenue Consensus
    $280000
    Range$280000 - $280000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$-0.03---
    Dec 26EST
    		-$-0.02---
    Sep 26EST
    		-$-0.02---
    Jun 26
    Reported Aug 14
    		$-0.03$-0.02-50.00%Miss-102.7%
    Mar 26
    Reported Apr 3
    		$-0.02$-0.02+0.00%Beat-100.0%
    Dec 25
    Reported Feb 18
    		$-0.02$-0.02+0.00%Beat+0.0%
    Sep 25
    Reported Nov 14
    		$-0.02$-0.02+0.00%Beat+0.0%
    Jun 25
    Reported Aug 14
    		$-0.01N/A+50.67%Beat+50.7%
    Mar 25
    Reported Jun 27
    		$-0.01$-0.02+50.00%Beat+97.5%
    Dec 24
    Reported Feb 14
    		$-0.02$-0.03+33.33%Beat+60.0%
    Sep 24
    Reported Nov 12
    		$-0.02$-0.03+33.33%Beat+60.0%
    Jun 24
    Reported Aug 8
    		$-0.03$-0.03+0.00%Beat+25.0%
    Mar 24
    Reported Jun 24
    		$-0.40$-0.04-900.00%Miss-427.0%
    Dec 23
    Reported Feb 14
    		$-0.05$-0.04-25.00%Miss-17.9%
    Sep 23
    Reported Nov 9
    		$-0.05$-0.05+0.00%Beat-6.8%
    Jun 23
    Reported Jul 7
    		$-0.04$0.00N/AMiss+20.0%
    Mar 23
    Reported Jun 30
    		$-0.08N/AN/ABeat+41.6%
    Dec 22
    Reported Feb 14
    		$-0.04N/AN/ABeat+15.2%
    Sep 22
    Reported Nov 1
    		$-0.05N/AN/ABeat+48.0%
    Jun 22
    Reported Aug 8
    		$-0.05N/AN/ABeat-25.0%
    Mar 22
    Reported Jun 22
    		$-0.13N/AN/ABeat-85.7%
    Dec 21
    Reported Feb 10
    		$-0.05N/AN/ABeat+16.7%
    Sep 21
    Reported Oct 29
    		$-0.09N/AN/ABeat-125.0%
    Jun 21
    Reported Aug 11
    		$-0.04N/AN/ABeat+20.0%
    Mar 21
    Reported Jun 14
    		$-0.07N/AN/ABeat+12.5%
    Dec 20
    Reported Feb 12
    		$-0.06N/AN/ABeat-50.0%
    Sep 20
    Reported Nov 20
    		$-0.04N/AN/ABeat-33.3%
    Jun 20
    Reported Jul 13
    		$-0.05N/AN/ABeat-66.7%
    Mar 20
    Reported Jun 17
    		$-0.08N/AN/ABeat-100.0%
    Dec 19
    Reported Feb 10
    		$-0.04N/AN/ABeat-33.3%
    Sep 19
    Reported Nov 6
    		$-0.03N/AN/ABeat+0.0%
    Jun 19
    Reported Aug 9
    		$-0.03N/AN/ABeat-50.0%
    Mar 19
    Reported Jun 17
    		$-0.04N/AN/ABeat-142.4%
    Dec 18
    Reported Feb 12
    		$-0.03N/AN/ABeat-50.0%
    Sep 18
    Reported Oct 16
    		$-0.03N/AN/ABeat-200.0%
    Jun 18
    Reported Aug 2
    		$-0.02N/AN/ABeat-100.0%
    Mar 18
    Reported Jun 21
    		$-0.02$0.00N/AMiss+1.2%
    Dec 17
    Reported Feb 20
    		$-0.02N/AN/ABeat+47.2%
    Sep 17
    Reported Nov 20
    		$-0.01N/AN/ABeat-143.9%
    Jun 17
    Reported Jul 14
    		$-0.01N/AN/ABeat-
    Mar 17
    Reported Jun 30
    		$-0.02$0.00N/AMiss-
    Dec 16
    Reported Feb 21
    		$-0.04N/AN/ABeat-
    Sep 16
    Reported Nov 21
    		$-0.00N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-3.31EV/EBITDA27.31x
    Price/FCF-5.44xFCF Yield-18.39%
    Profitability
    Profit Margin0.00%Operating Margin-1051.00%
    ROE-83.30%ROIC-95.03%
    Financial Health
    Debt/Equity0.15xInterest CoverageN/A
    Current Ratio0.40xQuick Ratio0.17x
    Trading Statistics
    Beta0.46Avg Volume1.07M
    52-Week High$0.4752-Week Low$0.24

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.30
    SMA 20$0.29
    SMA 50$0.27
    SMA 200$0.29
    EMA 10$0.30
    EMA 20$0.29
    EMA 50$0.28
    EMA 200$0.29

    MACD

    Line: 0.01Signal: 0.01Hist: 0.00

    ADX

    ADX: 26.8+DI: 29.7-DI: 15.7

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down8.0
    PSAR$0.29

    Bollinger Bands

    Upper Band$0.33
    Lower Band$0.24
    %B Position3204%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    54.3

    Momentum Oscillators

    Stoch %K62.2
    Stoch %D79.1
    Williams %R-61.6
    ROC (10d)6.4%
    Momentum0.02
    CCI (20d)67.8
    MFI (14d)82.1

    Volatility Measures

    ATR (14d)$0.02(5.7%)
    StdDev (20d)0.02
    Hist Vol69.3%(High)

    Volume Flow

    VWAP$0.30
    OBV90.3M
    AD Line53.8M
    CMF (20d)0.308

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.6x
    VWMA (20d)$0.30

    Pivot Points

    R3$0.36
    R2$0.35
    R1$0.33
    Pivot Point$0.32
    S1$0.30
    S2$0.29
    S3$0.27

    Advanced Oscillators

    TSI21.38
    Ultimate Osc52.9
    KST140.64

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$317,000$350,000$265,000$317,000$330,000$257,000$328,000$330,000$295,000$204,000$291,000$555,000
    Cost of Revenue$262,000$306,000$217,000$262,000$176,000$153,000$174,000$176,000$124,000$71,000$117,000$300,000
    Gross Profit$55,000$44,000$48,000$55,000$154,000$104,000$154,000$154,000$171,000$133,000$174,000$255,000
    Operating Expenses$2.51M$2.98M$2.83M$2.51M$1.57M$1.98M$2.06M$1.57M$3.06M$5.75M$2.67M$2.39M
    R&D$1.27M$1.48M$1.39M$1.27M$997,000$852,000$851,000$997,000$855,000$903,000$1.27M$747,000
    SG&A$1.24M$1.50M$1.44M$1.24M$569,000$1.13M$1.21M$570,000$1.49M$2.23M$1.40M$1.65M
    Operating Income$-2,458,000$-2,941,000$-2,784,000$-2,458,000$-1,412,000$-1,878,000$-1,905,000$-1,413,000$-2,170,000$-2,998,000$-2,491,000$-2,139,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$152,000$0$0$0$0$0$715,000$2.59M$0$0
    Income Before Tax$-2,402,000$-726,000$-2,936,000$-2,402,000$-1,197,000$-1,829,000$-1,599,000$-1,198,000$-2,885,000$-5,589,000$-2,451,000$-2,075,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,402,000$-726,000$-2,936,000$-2,402,000$-1,197,000$-1,829,000$-1,599,000$-1,198,000$-2,885,000$-5,589,000$-2,451,000$-2,075,000
    EBITDA$-2,344,000$-662,000$-2,880,000$-2,344,000$-2,341,000$-1,672,000$-1,458,000$-1,044,000$-1,999,000$-2,806,000$-2,293,000$-1,920,000
    EBIT$-2,402,000$-726,000$-2,936,000$-2,402,000$-2,495,000$-1,829,000$-1,599,000$-1,198,000$-2,163,000$-2,966,000$-2,451,000$-2,075,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IGC

    News

    IGC Pharma earnings matched, revenue fell short of estimates

    IGC Pharma reported its first-quarter earnings, matching analyst expectations for EPS at $-0.0200. However, the company's revenue of $164K fell short of the consensus estimate of $230K. The stock has seen a decline of -3.08% in the last three months and -24.63% over the past year.

    Investing.com•8/18/26•
    Somewhat-Bearish

    IGC Pharma Releases Q2 2026 Financial Results

    IGC Pharma, Inc. (IGC) has released its Q2 2026 financial results, reporting a basic and diluted EPS of -$0.03. The company generated $265,000 in revenue, marking a 19.2% year-over-year decrease, and posted a net loss of $3.0 million. Analyst consensus currently rates IGC with 4 buy, 1 hold, and 0 sell recommendations.

    AlphaStreet•8/17/26•
    Bearish

    IGC Pharma Q2 Results: CALMA Nears Enrollment Closure

    IGC Pharma announced its Q2 2026 financial results, highlighting that its CALMA Alzheimer's trial for IGC-AD1 is nearing enrollment closure, with topline data expected in Q4 2026. Management also elected to convert $1.15 million owed to them into common stock, aligning their interests with shareholders and preserving company cash. Additionally, the company received authorization in Colombia to conduct psilocybin-related development activities for neuropsychiatric symptoms.

    ACCESS Newswire•8/17/26•
    Somewhat-Bullish

    IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

    IGC Pharma announced its Q2 2026 financial results, highlighting that its CALMA Phase 2 trial for IGC-AD1, a therapeutic candidate for Alzheimer's disease agitation, is nearing enrollment completion with only six randomizations remaining. The company anticipates a Phase 2 topline readout in Q4 2026 following patient follow-up, database lock, and unblinding. Additionally, IGC Pharma reported on managing its equity, recent psilocybin authorization in Colombia, and continued development of AI-enabled platforms.

    Eagle-Tribune•8/17/26•
    Bullish

    IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

    IGC Pharma announced its Q2 2026 financial results, highlighting that its CALMA Alzheimer's trial is now within six randomizations of enrollment closure. The company expects the Phase 2 topline readout in Q4 2026. Management also converted approximately $1.6 million of debt into common stock to reduce obligations and preserve cash.

    Weatherford Democrat•8/17/26•
    Bullish

    Frequently Asked Questions About IGC

    Does IGC pay dividends?
    India Globalization Capital Inc (IGC) does not currently pay a regular dividend.
    What is IGC's market cap?
    India Globalization Capital Inc (IGC) has a market capitalization of $32.05M with a current stock price of $0.30.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In